Infertility and sterility
Education on Infertility and sterility and Alpha-1 Antitrypsin research from the Mark Egly Foundation, with patent claims clearly labeled as hypothesis.
Research hypothesis, not medical advice
The connections described on this page come from Mark Egly's patent filing and ongoing research. They are not established medical facts. Always work with your physician for diagnosis and treatment.
Research hypothesis. The connection between Infertility and sterility and Alpha-1 Antitrypsin is described in Mark Egly's 2020 patent filing. This is not established medical fact and is not medical advice. Always talk with your doctor about your own health.
What is Infertility and sterility?
Infertility and sterility is a health condition discussed in Mark Egly's research on Alpha-1 Antitrypsin. Reproductive conditions affect fertility and reproductive organs.
What Mark Egly's patent discusses
As shown by Mueller et al, neutrophils infiltrating the endometrium express vascular endothelial growth factor, potentially have a role in endometrial angiogenesis. This potential role in endometrial angiogenesis is also indicative of a role of neutrophils in female fertility and sterility. As a powerful inhibitor of neutrophils, in one embodiment AAT may be used to treat, control, or prevent female infertility and sterility, either in patients with or without known AATD. A diagnosis of infertility or sterility may prompt a medical provider to test a patient for AATD. Alternatively, a patient diagnosed with infertility or sterility may seek genetic testing for AATD through an independent genetic testing company such as 23andMe or geneology.com, a pharmaceutical company supplied test kit or other private methods available. A method for treating a patient suffering from infertility or sterility with AAT begins with the step of determining if the patient is AAT deficient or has lower AAT levels without being AATD. Determining if the patient is AAT deficient or has lower AAT levels without being AATD proceeds as previously described in this disclosure in the section entitled "Determin…
How this may relate to Alpha-1
Mark Egly's patent proposes that when the body has too little working Alpha-1 Antitrypsin, or when neutrophils release too much neutrophil elastase, inflammation and tissue damage may worsen. For Infertility and sterility, the patent suggests that testing for AATD or low circulating AAT could help guide care. This is a research hypothesis, not a proven treatment path for everyone with this condition.
What you can do
If you or a family member lives with Infertility and sterility, consider learning about Alpha-1 Antitrypsin Deficiency and discussing AAT testing with your healthcare team. The Mark Egly Foundation offers education and community support: